Kornimate/medical-research-clean huggingface dataset:
chemopreventive effect of combination of celecoxib and metformin in patients with familial adenomatous polyposis

Conditions: Familial Adenomatous Polyposis

Summary: familial adenomatous polyposis (fap) leads to adenomas and eventual adenocarcinomas in colon and less frequently, duodenum. chemopreventive strategies have been studied in fap patients to delay the development of adenomas and cancers. the non-steroidal anti-inflammatory drugs (nsaids) and selective cyclooxygenase-2 inhibitor have shown the regression of colorectal and duodenal adenomas in fap patients. however, these drugs showed gastrointestinal damage and cardiovascular risks, and new preventive strategies are needed. metformin, an anti-diabetic drug, has recently been suggested to have a suppressive effect on tumorigenesis via inhibition of mtor pathway, and have an inhibitory effect on polyp recurrence after removal of sporadic colorectal polyps. in addition, metformin has a number of potential mechnisms of carciovascular bebefit. we devised a randomized, open-label, comparative study to evaluate the effect of combination of celecoxib and metformin on polyps of colorectum and duodenum in fap patients.

this clinical trial is a randomized, open-label, comparative study to evaluate the effect of combination of celecoxib and metformin on polyps of colorectum and duodenum in fap patients. fap patients, satisfied an enrollment criteria, will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months. the base-line and six-month endoscopic examination (colonoscopy/sigmoidoscopy and upper gastrointestinal endoscopy) will be recorded, and photographs will be taken at the tattoo-marked area. the number and size of polyps, and a qualitative assessment of the total extent of polyposis will be measured.

Eligibility criteria:
inclusion criteria: - 1. patients with familial adenomatous polyposis(fap) who are 20 to 55 years of age. 2. fap patients who have colonic or duodenal polyp. 3. fap patients who have five or more polyps 2mm or more in diameter in endoscopic examination. exclusion criteria: * 1. fap patients who had a history of colectomy within the previous 12 months or need to undergo colectomy within 8 months after randomization. 2. fap patients with malignant disease, including colorectal cancer. 3. fap patients who used nsaids (non-steroidal anti-inflammatory drugs) or aspirin three or more times a week within 3 months of randomization. 4. pregnant or breast-feeding patients. 5. patients with cardiovascular diseases, peptic ulcer diseases and diabetes. 6. patients with abnormal results of serum laboratory tests (renal function and liver function test).
comparing menghini-type needle and franseen-type needle in ebus-tbna for sarcoidosis

Conditions: Suspected Sarcoidosis

Summary: this randomized pilot clinical trial aims to examine whether sample collection with franseen-type needles are effective for the diagnosis of sarcoidosis, as defined by improved sample quality for pathological diagnosis compared to the conventional menghini-type needle.

this study is a prospective randomized control trial. more than 370 lymph nodes from approximately 128 patients with enlarged mediastinal and/or hilar lymph nodes (≥10 mm short-axis diameter on ct scan) and suspected sarcoidosis will be enrolled in this study. this is a single-center study conducted at the toronto general hospital. if consent is obtained, patients will be considered enrolled. the patients will then be assigned to either menghini-type (the standard needle type in toronto general hospital) or franseen-type needles in a 1:1 ratio with stratified randomization by the availability of rapid on-site cytology evaluation. an automated randomization program will be used to generate the randomization scheme for the study. samples from mediastinal and hilar lymph nodes will be obtained by ebus-guided menghini-type or franseen-type needle biopsy. post-procedural assessment will take place in the endoscopy recovery room and will include, but not limited to, monitoring of vital signs, signs of bleeding, and pulmonary status. as ebus-tbna is an outpatient procedure, patients will be discharged home after the procedure. specimens (cell pellet and/or tissue fragment) will be assessed by pathologists as per their usual practice. the pathologists will remain blinded to the allocated needle. specimens will be classified by their adequacy for histological assessment and diagnostic yield. in addition, total procedure time and mean number of needle passes to obtain tissue samples will be compared between the two study arms.

Eligibility criteria:
inclusion criteria: * -any adult patient aged 18 years or older with enlarged mediastinal and/or hilar lymph nodes * (≥10 mm short-axis diameter on a ct scan), suspected as having sarcoidosis based on clinical * history, physical exam, and other investigations, and booked for ebus-tbna. exclusion criteria: * -patients that are unable to provide informed consent - patients with lymphadenopathy strongly suspected to be secondary to other diseases based on * clinical history, physical exam, and/or other investigations (e.g., lung cancer, lymphoma, * infection).
a study to compare neostigmine vs sugammadex in length of pacu stay in patients undergoing sleeve gastrectomy surgery

Conditions: Postoperative Nausea and Vomiting; Respiratory Conditions Due to Other External Agents

Summary: the investigators will track bariatric patients who received sugammadex versus neostigmine in the post anesthesia care unit until discharge and assess their length of stay and possible nausea / vomiting / hypoxia episodes.

during their preadmission testing, patients planning to undergo sleeve gastrectomy bariatric surgeries will be consented (by having them sign consent forms) and recruited for the study. a trained individual will track these patients after the surgery in the post anesthesia care unit until discharge and assess their length of stay and possible nausea / vomiting. the exact time the investigators are looking to assess is patient arrival to the post anesthesia care unit until patient ready for discharge when the anesthesiologist writes the anesthesia evaluation. the time the reversal agent is administered during the start of skin closure until patient medically ready to leave the post anesthesia care unit will also be taken into account. blinded to the treatment group, the trained individual will ask each patient every 15 minutes after arrival to the post anesthesia care unit if they are experiencing nausea or vomiting. as an exploratory measure, the trained individual will assess the patient at these same times (every 15 minutes) and determine their oxygen saturation. the investigators will take all the data from the observations and use statistical means to measure what is significant. a discussion and conclusion will follow. finally, the principal investigator will submit the study outcomes to an anesthesia journal.

Eligibility criteria:
inclusion criteria: * patients having sleeve gastrectomy * surgeries performed by a particular surgeon - dr. sam wasser * body mass index greater than 35 * american society of anesthesiologists score ii and iii patients exclusion criteria: * patients having a different type of bariatric surgery including but not limited to duodenal switch, gastric bypass, hand-assisted laparoscopic sleeve gastrectomy * sleeve gastrectomy's performed by other surgeons than dr. sam wasser. * pregnancy * allergic to sugammadex, zofran or scopolamine * chronic obstructive pulmonary disease or asthma that is uncontrolled * american society of anesthesiologists score i, iv, v patients

Keywords: sugammadex post anesthesia care unit recovery
psp as indicator for urinary sepsis in icu

Conditions: Urinary; Sepsis

Summary: sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. for clinical operationalization, organ dysfunction can be represented by an increase in the sequential organ failure assessment (sofa) score of 2 points or more, which is associated with an in-hospital mortality greater than 10%. pancreatic stone protein has been studied as biomarker of sepsis and results suggests that it has higher diagnostic performance. the main objective of this study is to identify ability of pancreatic stone protein (psp) as a new biomarker for diagnosis of urosepsis in intensive care units comparison to other biomarkers and its role as a prognostic marker for mortality


Eligibility criteria:
inclusion criteria: * adult ill patients at the icu aged more than 18 years old who at risk of urosepsis. * both males and females. exclusion criteria: * - age less than 18 years. * patients with a clinical diagnosis of sepsis at admission. * critically ill septic patients with a diagnosis other than urosepsis. * critically ill patients who were diagnosed to have urosepsis outside ain shams university intensive care and transferred to it. * malignant tumor patients. * uremic patients undergoing dialysis.
rouviere sulcus plane and hepatic hilum plane, which is better as a landmark in laparoscopic bile duct surgerys

Conditions: Cholelithiasis; Laparoscopic Cholecystectomy

Summary: rs and the rs plane are important anatomical markers in laparoscopic cholecystectomy. however, there are many variations in the shape and orientation of the rs, and the rs plane is an imaginary plane, which can be misjudged by different surgeons. the purpose of this study is to introduce a more intuitive anatomical marker and anatomical plane, hilum plane, and discuss the application value of hilum plane in laparoscopic biliary surgery by comparing it with rs and rs plane.

hepatic hilum plane is the hepatoduodenal serosa plane that extends from the base of the liver iva segment down to the first segment of the gallbladder triangle. during the operation, first pulling the gallbladder to the head side, using the separating forceps to slide down horizontally from the hilum (the basement of hepatic segment ⅳ), and along the serous of hepatoduodenal ligament, that is so called "hilum plane". it forms a "neck-shoulder" structure when the hilar plane meets the tent-like hepatobiliary triangle. the serosa of hepatobiliary triangle was dissected on the neck area and ventral side of hilar plane, and the serosa of posterior triangle of the gallbladder was also cutted on the same extension line . in this process, the type and orientation of rs, the relationship between the plane of the rs sulcus and the plane of the hilar plane were also recorded and compared with hilum plane.

Eligibility criteria:
inclusion criteria: benign disease of the gallbladder requires surgery exclusion criteria: patients with severe cirrhosis or had a history of partial hepatectomy were excluded from the statistics . patients with unexpected gallbladder carcinoma.

Keywords: anatomy
hr+/ her2- advanced/ metastatic breast cancer real world treatment patterns and outcomes

Conditions: Breast Cancer

Summary: this is a retrospective, observational study that will document the treatment patterns and clinical outcomes of patients diagnosed with hr+/her2- a/mbc who received cdk4/6i combination therapy with aromatase inhibitors (ai) as the initial endocrine-based therapy in the a/mbc setting.


Eligibility criteria:
inclusion criteria: 1. female or male sex. 2. diagnosis (confirmed by clinical review) of a/mbc, defined as breast cancer at stage iiib, stage iiic, stage iv or identified as having distant metastasis. 3. age ≥18 years at a/mbc diagnosis. 4. initiated a cdk4/6i in combination with an ai as initial endocrine-based therapy after a/mbc diagnosis on or after 2/3/2015 and before 4/1/2019. •note that the date of the start of the inclusion period reflects the month that the first cdk4/6i (ie, palbociclib) received u.s. fda approval. 5. evidence of er or pr positive disease, or absence of any indication of er and pr negative disease closest to a/mbc diagnosis (ie, patients are eligible without affirmative indication of er/pr+ status as long as er/pr- indication is not present). 6. evidence of her2 negative disease, or absence of any indication of her2 positive disease closest to a/mbc diagnosis (ie, patients are eligible without affirmative indication of her2- status as long as her2+ indication is not present). exclusion criteria: 1. enrollment in an interventional clinical trial for a/mbc during the study observation period.
online mindfulness-based tic reduction

Conditions: Tourette Syndrome; Tic Disorders

Summary: tourette syndrome (ts) and persistent tic disorder (ptd) are chronic and potentially disabling neurobiological conditions. although a range of pharmacological and psychosocial treatments exists, a significant number of individuals either do not respond to the current treatments, find them unacceptable, or cannot access them. thus, it is essential that researchers continue to pursue novel treatment approaches that can also be easily disseminated to those in need. initial pilot data suggest that a mindfulness-based intervention may be beneficial for adults with tic disorders. in the present study, the researchers aim to further develop this mindfulness-based intervention, adapt it to be delivered online and pilot test the intervention with a small group of participants. the data from this pilot test will inform a subsequent randomized controlled trial comparing online mindfulness-based tic reduction to online psychoeducation, relaxation, and supportive therapy. the specific aim is to determine the feasibility and acceptability of online mindfulness-based tic reduction in 6 adults with ts or ptd. the researchers hypothesize that online mindfulness-based tic reduction will be feasible and acceptable to adults with tic disorders as measured by participant satisfaction, qualitative participant feedback, home practice compliance, dropout, and adverse events.


Eligibility criteria:
inclusion criteria: 1. 18 years of age or older, 2. possess a primary diagnosis of tourette syndrome or persistent tic disorder, 3. fluent in english 4. residing in the united states, 5. either not be taking any tic suppressant medication or other psychotropic medication or be at a stable dose for 8 weeks prior to the baseline assessment and throughout the study exclusion criteria: 1. be receiving concurrent psychotherapy for the duration of the study 2. have prior extensive experience with mindfulness and/or meditation and 3. cannot have another medical or psychological condition that would prevent the individual from fully engaging in the study or require a higher level of care (e.g., suicidality).

Keywords: tic disorders mindfulness meditation online internet-based treatment
sonoelastographic changes after low energy extracorporeal shock wave therapy (eswt) in plantar fasciitis

Conditions: Chronic Plantar Fasciitis

Summary: extracoporeal shock wave therapy(eswt) was perfomed on the plantar fascia of chornic plantar fasciitis patients. pre-eswt and post-eswt pain intensity, sonography and sonoelastrography of the plantar fascia was checked. our hypothesis is that the plantar fascia stiffness increased after eswt as clinical symptom improves.

for patient who met the inclusion criteria, we check sonography and sonoelastography for their plantar fascias and obtain a thorough evulation questionaire for clinical symptom and pain condition and intensity in various conditions, also sf-36 questionaire first. inform consent was done. after the eswt, we follow patient with questionaire and sonography/sonoelastography at 1-week, 1-month, 3-month, 6-month, 9-month, and 12-month post-eswt time. the colored sonoelastographic image was analysed by computer software "image-j" with hue analysis method and relative stiffness of selected area within proximal plantar fascia wasa obtained for statistical analysis.

Eligibility criteria:
inclusion criteria: * pain for more than 6 months，poor response to the conservative treatments * sonography showed plantar fasciitia\>4.0mm) exclusion criteria: * acute infection of soft tissue/bone * malignant primary disease * blood coagulation disorders * pregnancy * patients with pacemaker * foot deformity
chlorhexidine gluconate bathing education video among hospitalized patients

Conditions: Infections

Summary: chlorhexidine gluconate (chg) bathing is an effective intervention to reduce hospitalized patient's risk of acquiring a central line-associated bloodstream infection (clabsi). while daily chg bathing for hospitalized patients is widely supported in the literature, patient adherence with this practice is suboptimal. written and verbal information is provided to patients by nursing staff regarding the importance of chg bathing and the correct usage of the chg cloths; however, these methods can be hindered by literacy and language barriers. medical videos have become popular avenues to provide necessary education to patients, and have been shown to improve patient-reported outcomes. whereas the benefits of educational videos has been described in previous studies on advanced care planning and postoperative quality of life, they have not been described for chg bathing. in this study, we aim to provide education (including the rationale/importance of chg bathing, and the appropriate process for bathing) through the use of a short video provided to hospitalized patients. the purpose of this study is to evaluate the use of medical videos to educate patients on chg bathing while hospitalized in the inpatient setting.

for this study, approximately 16 inpatient units will be included; 8 will be randomized to the intervention (access to patient-facing chg video) with the remaining units continuing with usual care (providing education via verbal/written information). all patients who require a chg bath would be eligible to participate. intervention group: in addition to the current educational document available for chg bathing, patients admitted to the intervention units will be provided access to a chg bathing video through multiple avenues (qr codes placed in the room/unit, video provided on unit ipads). nurses will be instructed to provide qr codes to patients to scan and watch the video. patients can scan the qr code using their own smart device or through unit-based ipads. after viewing the video, patients will be directed to scan a separate qr code to complete a voluntary questionnaire. control group: patients in the control group would have access to the current education available (patient education document) - usual care

Eligibility criteria:
inclusion criteria: * patients admitted to an intervention unit who require a chg skin treatment exclusion criteria: * chg allergy * patients on comfort care
retrospective case study examining patient outcomes compared to the chemofx assay in endometrial cancer patients

Conditions: Endometrial Cancer

Summary: the purpose of this study is to assess the relationship of assay sensitive patients versus assay resistant patients with progression free survival.

this is a multicenter, retrospective chart review study of de-identified drug response marker results and a limited data set of clinical outcome data. data from approximately 70 cases will be collected from approximately 10 study sites and correlated to the chemofx drug response marker results. the outcome of progression free survival will be defined as the period of time between the first dose of chemotherapy following the report of the marker result until clinical progression or death. objective response will be measured from the first dose of chemotherapy following the report of the marker result until progression or change in therapy. overall survival will be measured from the start of chemotherapy to the actual date of death.

Eligibility criteria:
inclusion criteria: * case has an original pathology report showing stage iii, iiia, iiib, iiic, iv, iva, ivb, or recurrent endometrial cancer. * case includes a pathology or cytology report from initial diagnosis showing disease of one or more of the following histologic epithelial cell types: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, transitional cell carcinoma, clear cell carcinoma, or adenocarcinoma, not otherwise specified (n.o.s.). * case has been identified for pattern of response evaluation. * case must have a commercial chemofx drug response marker final report. exclusion criteria: * cases of patients who were deceased prior to 1 cycle of chemotherapy.

Keywords: late stage
impact of a resource-based life review intervention on advanced cancer patients

Conditions: Advanced Cancer

Summary: the main objective of the present study is to evaluate the effects of the revie ⊕ intervention on the self-esteem of patients diagnosed with an advanced cancer. a pragmatic, two-arm parallel-group, waitlist randomized controlled trial is conducted. the study takes place in the oncology department of the university hospitals of geneva at 3 outpatient units.

the main objective of the present study is to evaluate the effects of the revie ⊕ intervention on the self-esteem of patients diagnosed with an advanced cancer. the secondary objectives are to evaluate the effects of the revie ⊕ intervention on spiritual well-being, personal development, life satisfaction, and the perception of the interaction with the nurses. a pragmatic, two-arm parallel-group, waitlist randomized controlled trial (wlrct) is conducted in which participants are randomized into (i) intervention, or (ii) waitlist control groups. the intervention group (ig) receives the revie ⊕ intervention early on and the control group (cg) the same intervention but later on (i.e., after eight weeks).this monocentric study takes place in the oncology department of the university hospitals of geneva (hug) at two outpatient units (planned n=102; 51 per group).

Eligibility criteria:
inclusion criteria: * adults 18 years with and advanced cancer, * whose general health status is adequate for participation in the study based on a clinical assessment by the nurse / doctor; and * who consent to participate in the study. exclusion criteria: * documented cognitive impairment that compromises capacity for discernment, * command of french is insufficient for reading, writing, or conversing.

Keywords: resource-based self-esteem life review intervention
the knowledge, attitudes and practices of healthcare workers on drug hypersensitivity reactions in children

Conditions: Adverse Drug Reactions

Summary: adverse drug reactions are an important public health consern that affects physician prescriptions and practice. the responsibilities of healthcare professionals in monitoring, prevention, treatment and reporting of drug hypersensitivity reactions and drug allergies are essential for patient safety. providing drug safety must be one of the main goals to be achieved for every member of our society. in our study, we planned to evaluate the knowledge, attitudes, and behaviors of healthcare workers in our country about drug hypersensitivity reactions in pediatric patients and to determine the risk factors that may affect them.

this study was carried out in a capital-located university hospital with a capacity of 1150 beds. healthcare workers who are authorized to intervene in children (0-18 age group) including medical doctors, nurses and dentists were enrolled to study. in the evaluation of the knowledge, attitudes, and behaviors of the participants about drug hypersensitivity reactions in children, a study questionnaire was developed by pediatric allergy and immunology specialists and pediatric nurses by considering the other studies on the same subject.

Eligibility criteria:
inclusion criteria: the study included healthcare workers including medical doctors, nurses and dentists who perform interventions on children (0-18 years of age). exclusion criteria: -

Keywords: healthcare workers adverse drug reactions